New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Contributed by: Business Wire

Logo

Tags

Biotechnology

Neurology

Health

Pharmaceutical

Clinical Trials

AJOVY, Migraine Prevention, new data

More Like This

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

PR Newswire associated0

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

PR Newswire associated0

Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in Europe

PR Newswire associated0

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress